In 1946, Nordisk was able to form crystals of protamine and insulin and marketed it in 1950 as NPH insulin. NPH insulin has the advantage that it can be mixed with an insulin that has a faster onset to complement its longer lasting action, which is the primary reason NPH remains on the market today, because manufacturers sell a variety of premixed insulin formulations. However, numerous medical studies have suggested that NPH has one of the least consistent absorption rates when injected subcutaneously, and a majority of head-to-head comparisons with Lente insulin usually found Lente provided superior glycemic control.
Eventually all animal insulins made by Novo Nordisk were replaced by synthetic, recombinant 'human' insulin. Synthetic 'human' insulin is also complexed with protamine to form NPH. NPH insulin is cloudy and has an onset of 1-4 hours. Its peak is 6-10 hours and its duration is about 10 -16 hours.
Administration
NPH insulin may be combined with faster acting insulin to allow more accurate dosing and better blood sugar level control. When administered this way, the two insulin types will normally be combined in the same syringe. NPH and fast-acting insulin bind when mixed, so they should not be combined until it is time to inject. Patients are instructed on the proper procedure to prepare this type of injection to minimize the likelihood of combining two types of insulin in the same vial. The proper order for withdrawing NPH insulin and fast-acting insulin into the same syringe can be remembered by the mnemonic "clear before cloudy", or fast acting clear insulin first, followed by NPH (cloudy). Aspiration, or pulling back on the plunger of the syringe after the needle has been injected to check for blood, is not appropriate for subcutaneous injections. 
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◾ Insulin analogue
